News | Heart Failure | September 18, 2019

FDA Grants Fast Track Designation for Farxiga in Heart Failure

FDA approves accelerated development for dapagliflozin for adults with heart failure with reduced ejection fraction or preserved ejection fraction

FDA Grants Fast Track Designation for Farxiga in Heart Failure

September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure. The designation applies to adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

The FDA’s Fast Track program is designed to accelerate the development and review of new medicines for the treatment of serious conditions where there is an unmet treatment need.

The Fast Track designation is based on two Phase III trials, DAPA-HF and DELIVER, which investigated the role of FARXIGA in patients with heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF), respectively. The results of DAPA-HF, presented at the 2019 European Society of Cardiology (ESC) Congress, Aug. 31-Sept. 4 in Paris, France, showed Farxiga reduced the composite of CV death or worsening of heart failure by 26 percent (p<0.0001) and showed a reduction in each of the individual components of the composite endpoint.

Farxiga is currently approved as a monotherapy and as part of combination therapy to improve glycemic control in adults with type 2 diabetes (T2D). In August 2019 the FDA granted Fast Track designation for the development of Farxiga to delay the progression of renal failure and prevent CV and renal death in patients with chronic kidney disease. Farxiga is not indicated to reduce the risk of HF, CV death or kidney disease.

Read the article “Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure”

FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations — October 2019 update

For more information: www.escardio.org


Related Content

News | ESC

March 23, 2023 — Newly-published research has debunked the idea that there is an “obesity paradox,” whereby patients ...

Home March 23, 2023
Home
News | ESC

March 17, 2023 — Discover what’s new and on the horizon in the prevention and treatment of heart rhythm disorders at ...

Home March 17, 2023
Home
News | ESC

March 10, 2023 — The first evidence that exceeding the World Health Organization (WHO) ozone limit is associated with ...

Home March 11, 2023
Home
News | ESC

September 1, 2022 — “At ESC Congress in Barcelona, we discussed the newest science in the light of our collective ...

Home September 01, 2022
Home
News | ESC

August 30, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest ...

Home August 30, 2022
Home
News | ESC

August 30, 2022 — A pill containing aspirin and medications to lower lipids and blood pressure more effectively prevents ...

Home August 30, 2022
Home
News | ESC

August 30, 2022 — Abbott announced new late-breaking data that show its HeartMate 3 heart pump extends survival of ...

Home August 30, 2022
Home
News | ESC

August 29, 2022 — Amarin Corporation plc announced that new REDUCE-IT data show that VASCEPA/VAZKEPA (icosapent ethyl) ...

Home August 29, 2022
Home
News | ESC

Organizers of the European Society of Cardiology (ESC) Congress have released plans and announced 10 Hot Line Sessions ...

Home July 22, 2022
Home
News | ESC

June 1, 2022 — Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease ...

Home June 01, 2022
Home
Subscribe Now